Avrio Biopharmaceuticals receives Cal FDB approval to manufacture and ship pharmaceutical products

Avrio Biopharmaceuticals, LLC, a wholly-owned subsidiary of Irvine Pharmaceutical Services, Inc., received approval to manufacture and ship pharmaceutical products by the California Department of Public Health, Food and Drug Branch (Cal FDB), completing the organization's portfolio of product development services in support of its pharmaceutical, biopharmaceutical, and medical device clients.  

Avrio's newly built, 20,000 square foot, state-of-the-art, aseptic fill-and-finish facility includes three aseptic suites and five production suites with each suite having its own dedicated air handling system. With great confidence in the newly built infrastructure, strategic manufacturing-process flow, state-of-the-art equipment, and experienced staff, Avrio boasts its level of quality by offering clients live video viewing of production (along with on-site viewing access). In addition to a production area designed to provide clients flexibility and scalability, Avrio also includes laboratory space for quality control, microbiology, formulation, and a pilot suite. Furthermore, Avrio's affiliate, Irvine Pharmaceutical Services, Inc., located just across the street, has over 65,000 square feet of laboratory space which provides complete cGMP analytical CMC support.

With multiple manufacturing contracts in place and a number of agreements underway, Avrio has continued to value the core principles of its affiliate, Irvine Pharmaceutical Services.  "For the past 22 years we have been dedicated to continual improvement of our systems and infrastructures in order to better serve the needs of our clients," said Assad J. Kazeminy, CEO and Founder of Irvine Pharmaceutical Services. "With the addition of Avrio, we can now support our clients from start to finish via a seamless partnership."